Eli Lilly And Company

This study tests whether donanemab, a monthly infusion, can slow or prevent memory and thinking decline in people who have early signs of Alzheimer's but no symptoms yet. About 3,000 participants with brain changes linked to Alzheimer's will receive either donanemab or a placebo …

This study looks at how the drug LY3537031 moves through the body in people with different levels of kidney function. About 32 adults—some with kidney problems and some healthy—will receive a single dose. The goal is to learn how the kidneys affect drug levels and safety, not to …